The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...
FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
Obstructive sleep apnea happens when a person's upper airway becomes blocked ... The drug's active ingredient, tirzepatide, is marketed as Zepbound for weight loss and Mounjaro as a diabetes treatment ...
Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...